IRF6 in development and disease: A mediator of quiescence and differentiation

Cell Cycle

Volumn 7, Issue 13, 2008, Pages 1925-1930

  Bailey, Caleb M ^a,b   Hendrix, Mary J C ^a,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b STOWERS INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c CHILDREN S MEMORIAL RESEARCH CENTER   (United States)

Author keywords

Breast cancer; Cell differentiation; IRF6; Mammary gland; Maspin

Indexed keywords

I KAPPA B KINASE ALPHA; INTERFERON REGULATORY FACTOR 6; MASPIN; PROTEIN 14 3 3; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR;

BREAST CANCER; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; CELL CYCLE G0 PHASE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; HUMAN; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 47749085499     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.13.6221     Document Type: Review

References (52)

1. Bailey CM, Khalkhali-Ellis Z, Kondo S, Margaryan NV, Seftor RE, Wheaton WW, Amir S, Pins MR, Schutte BC, Hendrix MJ. Mammary serine protease inhibitor (Maspin) binds directly to interferon regulatory factor 6: identification of a novel serpin partnership. J Biol Chem 2005; 280:34210-7.
2. Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E, Sager R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994; 263:526-9.
3. Zhang M, Magit D, Botteri F, Shi HY, He K, Li M, Furth P, Sager R. Maspin plays an important role in mammary gland development. Dev Biol 1999; 215:278-87.
4. Bailey CM, Abbott DE, Margaryan NV, Khalkhali-Ellis Z, Hendrix MJ. Interferon regulatory factor 6 promotes cell cycle arrest and is regulated by the proteasome in a cell cycle-dependent manner. Mol Cell Biol 2008; 28:2235-43.
5. 0 exit. Cell 2004; 117:239-51.
6. Nakagawa K, Yokosawa H. Degradation of transcription factor IRF-1 by the ubiquitin-proteasome pathway. The C-terminal region governs the protein stability. Eur J Biochem 2000; 267:1680-6.
7. Xiong H, Li H, Kong HJ, Chen Y, Zhao J, Xiong S, Huang B, Gu H, Mayer L, Ozato K, Unkeless JC. Ubiquitin-dependent degradation of interferon regulatory factor-8 mediated by Cbl downregulates interleukin-12 expression. J Biol Chem 2005; 280:23531-9.
8. Saitoh T, Tun-Kyi A, Ryo A, Yamamoto M, Finn G, Fujita T, Akira S, Yamamoto N, Lu K P, Yamaoka S. Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1. Nat Immunol 2006; 7:598-605.
9. Richardson RJ, Dixon J, Malhotra S, Hardman MJ, Knowles L, Boot-Handford R P, Shore P, Whitmarsh A, Dixon MJ. Irf6 is a key determinant of the keratinocyte proliferation-differentiation switch. Nat Genet 2006; 38:1329-34.
10. Ingraham CR, Kinoshita A, Kondo S, Yang B, Sajan S, Trout KJ, Malik MI, Dunnwald M, Goudy SL, Lovett M, Murray JC, Schutte BC. Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6). Nat Genet 2006; 38:1335-40.
11. Herron BJ, Liddell RA, Parker A, Grant S, Kinne J, Fisher JK, Siracusa LD. A mutation in stratifin is responsible for the repeated epilation (Er) phenotype in mice. Nat Genet 2005; 37:1210-2.
12. Holbrook KA, Dale BA, Brown KS. Abnormal epidermal keratinization in the repeated epilation mutant mouse. J Cell Biol 1982; 92:387-97.
13. Guenet JL, Salzgeber B, Tassin M T. Repeated epilation: a genetic epidermal syndrome in mice. J Hered 1979; 70:90-4.
14. Hu Y, Baud V, Delhase M, Zhang P, Deerinck T, Ellisman M, Johnson R, Karin M. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science 1999; 284:316-20.
15. Descargues P, Sil AK, Sano Y, Korchynskyi O, Han G, Owens P, Wang XJ, Karin M. IKKalpha is a critical coregulator of a Smad4-independent TGFbeta-Smad2/3 signaling pathway that controls keratinocyte differentiation. Proc Natl Acad Sci USA 2008; 105:2487-92.
16. Blazkova H, von Schubert C, Mikule K, Schwab R, Angliker N, Schmuckli-Maurer J, Fernandez PC, Doxsey S, Dobbelaere DA. The IKK inhibitor BMS-345541 affects multiple mitotic cell cycle transitions. Cell Cycle 2007; 6:2531-40.
17. Prajapati S, Tu Z, Yamamoto Y, Gaynor RB. IKKalpha regulates the mitotic phase of the cell cycle by modulating Aurora A phosphorylation. Cell Cycle 2006; 5:2371-80.
18. 1- to S-phase progression. Embo J 2006; 25:3801-12.
19. Zhu F, Xia X, Liu B, Shen J, Hu Y, Person M. IKKalpha shields 14-3-3sigma, a G(2)/M cell cycle checkpoint gene, from hypermethylation, preventing its silencing. Mol Cell 2007; 27:214-27.
20. Dougherty MK, Morrison DK. Unlocking the code of 14-3-3. J Cell Sci 2004; 117:1875-84.
21. Dellambra E, Golisano O, Bondanza S, Siviero E, Lacal P, Molinari M, D'Atri S, De Luca M. Downregulation of 14-3-3sigma prevents clonal evolution and leads to immortalization of primary human keratinocytes. J Cell Biol 2000; 149:1117-30.
22. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K. Inactivation of the 14-3-3 sigma gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res 2000; 60:4353-7.
23. Leffers H, Madsen P, Rasmussen HH, Honore B, Andersen AH, Walbum E, Vandekerckhove J, Celis JE. Molecular cloning and expression of the transformation sensitive epithelial marker stratifin. A member of a protein family that has been involved in the protein kinase C signal-ling pathway. J Mol Biol 1993; 231:982-98.
24. 2/M progression. Mol Cell 1997; 1:3-11.
25. Chan TA, Hermeking H, Lengauer C, Kinzler K W, Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999; 401:616-20.
26. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001; 19:623-55.
27. Qin BY, Liu C, Lam SS, Srinath H, Delston R, Correia JJ, Derynck R, Lin K. Crystal structure of IRF-3 reveals mechanism of autoinhibition and virus-induced phosphoactivation. Nat Struct Biol 2003; 10:913-21.
28. Kondo S, Schutte BC, Richardson RJ, Bjork BC, Knight AS, Watanabe Y, Howard E, de Lima RL, Daack-Hirsch S, Sander A, McDonald-McGinn DM, Zackai EH, Lammer EJ, Aylsworth AS, Ardinger HH, Lidral AC, Pober BR, Moreno L, Arcos-Burgos M, Valencia C, Houdayer C, Bahuau M, Moretti-Ferreira D, Richieri-Costa A, Dixon MJ, Murray JC. Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes. Nat Genet 2002; 32:285-9.
29. Moynagh PN. TLR signalling and activation of IRFs: revisiting old friends from the NFkappaB pathway. Trends Immunol 2005; 26:469-76.
30. Becker MN, Diamond G, Verghese MW, Randell SH. CD14-dependent lipopolysaccharide-induced beta-defensin-2 expression in human tracheobronchial epithelium. J Biol Chem 2000; 275:29731-6.
31. Furrie E, Macfarlane S, Thomson G, Macfarlane G T. Toll-like receptors-2, -3 and -4 expression patterns on human colon and their regulation by mucosal-associated bacteria. Immunology 2005; 115:565-74.
32. Wolfs TG, Buurman WA, van Schadewijk A, de Vries B, Daemen MA, Hiemstra PS, van't Veer C. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFNgamma and TNFalpha mediated upregulation during inflammation. J Immunol 2002; 168:1286-93.
33. Mempel M, Voelcker V, Kollisch G, Plank C, Rad R, Gerhard M, Schnopp C, Fraunberger P, Walli AK, Ring J, Abeck D, Ollert M. Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol 2003; 121:1389-96.
34. 1 arrest. Nature 1985; 313:597-600.
35. Kip 1 during treatment with interferon-alpha in carcinoid tumor cells. J Biol Regul Homeost Agents 1999; 13:207-15.
36. Hasan UA, Trinchieri G, Vlach J. Toll-like receptor signaling stimulates cell cycle entry and progression in fibroblasts. J Biol Chem 2005; 280:20620-7.
37. Hasan UA, Caux C, Perrot I, Doffin AC, Menetrier-Caux C, Trinchieri G, Tommasino M, Vlach J. Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proc Natl Acad Sci USA 2007; 104:8047-52.
38. Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ, Sager R. Maspin acts at the cell mem-brane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci USA 1996; 93:11669-74.
39. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med 2000; 6:196-9.
40. Jiang N, Meng Y, Zhang S, Mensah-Osman E, Sheng S. Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene 2002; 21:4089-98.
41. Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJ. Biological functions of maspin. J Cell Physiol 2006; 209:617-24.
42. Chen EI, Florens L, Axelrod FT, Monosov E, Barbas CF, 3rd, Yates JR, 3rd, Felding-Habermann B, Smith J W. Maspin alters the carcinoma proteome. Faseb J 2005; 19:1123-4.
43. Odero-Marah VA, Khalkhali-Ellis Z, Chunthapong J, Amir S, Seftor RE, Seftor EA, Hendrix MJ. Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells. Cancer Biol Ther 2003; 2:398-403.
44. Cui JQ, Wang H, Reddy ES, Rao VN. Differential transcriptional activation by the N-terminal region of BRCA1 splice variants BRCA1a and BRCA1b. Oncol Rep 1998; 5:585-9.
45. Chiba H, Muramatsu M, Nomoto A, Kato H. Two human homologues of Saccharomyces cerevisiae SWI2/SNF2 and Drosophila brahma are transcriptional coactivators cooperating with the estrogen receptor and the retinoic acid receptor. Nucleic Acids Res 1994; 22:1815-20.
46. Coisy-Quivy M, Disson O, Roure V, Muchardt C, Blanchard JM, Dantonel JC. Role for Brm in cell growth control. Cancer Res 2006; 66:5069-76.
47. Muchardt C, Bourachot B, Reyes JC, Yaniv M. ras transformation is associated with decreased expression of the brm/SNF2alpha ATPase from the mammalian SWI-SNF complex. Embo J 1998; 17:223-31.
48. LeGouy E, Thompson EM, Muchardt C, Renard J P. Differential preimplantation regulation of two mouse homologues of the yeast SWI2 protein. Dev Dyn 1998; 212:38-48.
49. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
50. Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res 2003; 63:6424-31.
51. Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T, Lamphier MS, Aizawa S, Mak TW, Taniguchi T. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994; 77:829-39.
52. Kim TY, Lee KH, Chang S, Chung C, Lee HW, Yim J, Kim TK. Oncogenic potential of a dominant negative mutant of interferon regulatory factor 3. J Biol Chem 2003; 278:15272-8.